AXDXAccelerate Diagnostics, Inc

Nasdaq acceleratediagnostics.com


$ 0.76 $ 0.03 (4.55 %)    

Thursday, 18-Apr-2024 15:52:08 EDT
QQQ $ 422.80 $ -2.43 (-0.57 %)
DIA $ 377.76 $ 0.39 (0.1 %)
SPY $ 499.54 $ -1.03 (-0.21 %)
TLT $ 88.82 $ -0.45 (-0.5 %)
GLD $ 220.32 $ 0.75 (0.34 %)
$ 0.77
$ 0.75
$ 0.00 x 0
$ 0.00 x 0
$ 0.75 - $ 0.76
$ 0.73 - $ 11.90
34,997
na
9.61M
$ 1.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-14-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 03-02-2021 12-31-2020 10-K
14 11-06-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 02-28-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-01-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-01-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-05-2017 03-31-2017 10-Q
29 02-28-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-08-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-09-2016 12-31-2015 10-K
34 11-02-2015 09-30-2015 10-Q
35 07-31-2015 06-30-2015 10-Q
36 05-07-2015 03-31-2015 10-Q
37 02-26-2015 12-31-2014 10-K
38 11-04-2014 09-30-2014 10-Q
39 08-01-2014 06-30-2014 10-Q
40 05-02-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 craig-hallum-maintains-hold-on-accelerate-diagnostics-lowers-price-target-to-1

Craig-Hallum analyst Alexander Nowak maintains Accelerate Diagnostics (NASDAQ:AXDX) with a Hold and lowers the price target ...

 accelerate-diagnostics-q4-eps-089-misses-062-estimate-sales-303m-miss-345m-estimate

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

 why-accelerate-diagnostics-axdx-stock-is-down-38

Accelerate Diagnostics shares are trading lower by 38% during Friday's session. The company priced an underwritten public o...

 us-stocks-higher-schlumberger-earnings-beat-estimates

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market o...

 accelerate-diagnostics-announces-pricing-of-15m-public-offering-and-private-placement-the-public-offering-price-for-each-unit-is-150-and-the-public-offering-price-for-each-pre-funded-unit-is-149

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (the "Company") today announced the pricing of an underwritten public offeri...

 why-accelerate-diagnostics-axdx-stock-hit-a-new-52-week-low-today

Accelerate Diagnostics shares are trading lower by 23.2% Tuesday morning. The company announced the initiation of a proposed un...

 accelerate-diagnostics-has-launched-a-proposed-underwritten-public-offering-of-45m-each-consisting-of-one-share-of-common-stock-and-one-warrant-to-purchase-one-share-of-common-stock-terms-not-disclosed

The Company expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock an...

 accelerate-diagnostics-announces-certain-preliminary-q4-and-fy23-results-fy23-preliminary-revenue-was-121m-vs-128m-yoy-ended-the-year-with-134m-in-cash-and-cash-equivalents

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that i...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION